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Cellular metabolitesExcept for its redox properties, cytochrome c is an inert protein. However, dissociation of the bond between
methionine-80 and the heme iron converts the cytochrome into a peroxidase. Dissociation is accomplished by
subjecting the cytochrome to various conditions, including proteolysis and hydrogen peroxide (H2O2)-
mediated oxidation. In affected cells of various neurological diseases, including Parkinson's disease,
cytochrome c is released from the mitochondrial membrane and enters the cytosol. In the cytosol cytochrome
c is exposed to cellular proteases and to H2O2 produced by dysfunctional mitochondria and activated
microglial cells. These could promote the formation of the peroxidase form of cytochrome c. In this study we
investigated the catalytic and cytolytic properties of the peroxidase form of cytochrome c. These properties
are qualitatively similar to those of other heme-containing peroxidases. Dopamine as well as sulfhydryl
group-containing metabolites, including reduced glutathione and coenzyme A, are readily oxidized in the
presence of H2O2. This peroxidase also has cytolytic properties similar to myeloperoxidase, lactoperoxidase,
and horseradish peroxidase. Cytolysis is inhibited by various reducing agents, including dopamine. Our data
show that the peroxidase form of cytochrome c has catalytic and cytolytic properties that could account for at
least some of the damage that leads to neuronal death in the parkinsonian brain.iazoline-6-sulfonic acid) dia-
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Parkinson's disease is a neurodegenerative disease, usually
affecting older people. The disease is characterized by a selective
loss of dopaminergic neurons and the development of Lewy bodies in
the substantia nigra region of the brain. When symptoms ﬁrst appear
in patients, 60–70% of the neurons of the substantia nigra are already
degenerated and the striatal dopamine level is reduced by 80% [1,2].
Patients are commonly treated with levo-DOPA, in an attempt to
partly restore the dopamine that is lost during degeneration of the
neurons.
Although many studies have been conducted with patients as well
as with animal models attempting to inhibit the progression of the
disease, successful results have been scarce, perhaps due to the fact
that the cause of the disease is still obscure and many questions about
the processes involved in the progression of the disorder are still left
unanswered.
Based on a close examination of the aberrant products found in the
substantia nigra of Parkinson patients and assuming that theseproducts were generated by enzymatic action, we concluded that
these products appear to be the products of a heme peroxidase [3].
These enzymes are typically non-speciﬁc for their substrates to be
oxidized, but are speciﬁc for hydrogen peroxide as the reducing
substrate. Moreover, the oxidative energy available from the
peroxidase reaction is about 50 kcal/mol, which is sufﬁcient energy
to oxidize proteins, lipids and nucleic acids as well as many other
biological compounds [3].
Many cells contain peroxidases, but they are harmless because
normally H2O2 is only present at very low concentrations in vivo.
However, it is well established that in parkinsonian neurons
dysfunctional mitochondria produce abnormally high amounts of
H2O2, often also referred to as reactive oxygen species (ROS) [4].
Hence, this H2O2 could trigger a peroxidase into oxidizing various
important cellular components, eventually leading to neuronal death.
To test this hypothesis, we analyzed the substantia nigra of
several dogs some time ago, and found peroxidase activity to be
present in these tissues. We suggested at that time that the
oxidative damage that occurs in affected neurons of Parkinson's
disease may at least in part be catalyzed by a peroxidase [5]. Since
that time peroxidase activity has also been observed in a rat brain
homogenate [6] and in the substantia nigra of normal and
parkinsonian human brain tissues [7,8]. Unfortunately, much effort
notwithstanding, the identity of this endogenous peroxidase activity
has not yet been ﬁrmly established [9].
A second well established fact associated with parkinsonism is the
aberrant release of cytochrome c from the mitochondrial membrane
1139J. Everse et al. / Biochimica et Biophysica Acta 1812 (2011) 1138–1145[10,11]. This cytochrome c is known to be involved in triggering the
apoptotic pathway [12,13]. However, cytosolic cytochrome cmay also
be involved in other reactions.
The fact that cytochrome c can form a peroxidase by proteolytic
action has been known for about 50 years. Harbury and Loach [14]
showed that extensive treatment of cytochrome cwith pepsin yields a
heme moiety with as few as 8 to 20 amino acids remaining attached,
one of which is the heme-bound histidine. These products are known
as microperoxidases and are commercially available. These mini-
enzymes have been extensively studied over the past 30 years
(reviewed by [15]), and are known to not only catalyze oxidative
reactions but also possess cytolytic activity [16].
Native human cytochrome c is a heme protein with a molecular
weight of 12,384, containing 104 amino acid residues (Fig. 1). The
heme moiety is covalently bound to the protein by two cysteine
residues, and ligands 5 and 6 of the heme iron are both occupied:
ligand 5 is occupied by an imidazole nitrogen of histidine18, and ligand
6 is occupied by the sulfur atom of methionine80. As such, it has no
enzymatic activity because it has no substrate binding site. However, a
dissociation of the Fe―Met80 bond creates a free sixth ligand, that is
able to bind H2O2 in a manner similar to other heme peroxidases.
Hence, the only requirement for converting cytochrome c to a
peroxidase is a dissociation of the bond between Met80 and the
heme iron.
This information led us to the hypothesis that cytochrome c may
be involved in the early stages of Parkinson's disease and perhaps in
other neurological diseases as well [3,17]. Cytochrome c, before or
after its release from dysfunctional mitochondrial membranes may be
converted to its peroxidase form byH2O2 or by cytosolic proteases andFig. 1. Heme packing diagram of the cytochrome cmolecule. Heavy circles indicate side
chains that are buried on the interior of the molecule, and attached black dots mark
residues whose side chains pack against the heme, and dark half circles show groups
that are half-buried at the surface. Arrows from try59 and tyr48 to the buried propionic
acid group represent hydrogen bonds. From: Dickerson et al. [68], with permission.as such may at least in part be responsible for the oxidative and
cytolytic reactions that are hallmarks of neurodegenerative diseases
such as Parkinson's disease, Alzheimer's disease, and amyotrophic
lateral sclerosis (ALS).
In view of the potential role that the peroxidase form of
cytochrome c may play in the process of neurodegeneration, we
investigated the catalytic and cytolytic properties of this enzyme
(hereinafter referred to as cytochrome cpx in order to prevent
confusion with the bacterial enzyme already known for decades as
cytochrome c peroxidase). Our results indicate that cytochrome cpx
does possess the catalytic properties required to catalyze the types of
damage that are observed in parkinsonian brain cells.
2. Materials and methods
2.1. Materials
Cytochrome c and all other chemicals used in this study were
purchased from Sigma-Aldrich Chemical Corp., St. Louis, MO.
2.2. Methods
All experimentswere carried out at least in triplicate. Graphs of the
most representative results are shown in the ﬁgures.
2.2.1. Preparation of cytochrome cpx
Cytochrome c (5.5 mg) was dissolved in 4.4 ml distilled water and
the pH was adjusted to 2.6 with 1 N HCl. To the solution was added
10 μl of a 1 mg/ml pepsin solution and the mixture was incubated at
room temperature for 60 min. The pH was then adjusted to 7.5 with a
0.2 MNa2HPO4 solution and themixturewas chromatographed over a
Sephadex-25 column, equilibrated in distilled water, to remove the
pepsin. The column was eluted with distilled water and the colored
fractions were collected, dialyzed against 2 liters of distilled water
overnight, and lyophilized. Mass spectrophotometric analyses were
performed by the Center for Biotechnology and Genomics at Texas
Tech University.
2.2.2. Assay for peroxidase activity
Peroxidase activity was measured by determining the rate of
hydrogen peroxide-mediated oxidation of the commonly used
substrate 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) dia-
mmonium salt (ABTS) spectrophotometrically at 740 nm. Nine
hundred microliters of a 9.1 mM solution of ABTS in 0.1 M Na-
phosphate buffer, pH 5.5, was placed in a 1-ml cuvette, as well as
100 μl 100 mM H2O2 in the same buffer. The reaction was started by
the addition of 10–50 μl of the solution to be tested, and assays were
normally carried out for 3 min at room temperature. Measurements
were made with a Hewlett-Packard UV/vis spectrophotometer Model
8450A, equipped with a Model HP-89100A temperature controller.
Reference cuvettes contained the same ingredients as the sample
cuvettes, except for the peroxidase. This was done to correct for any
non-catalyzed oxidation of substrates.
Speciﬁc peroxidase activity is expressed as moles ABTS oxidized
per mole of cytochrome cpx (MW=12,384) per minute under the
conditions of the assay. H2O2 concentrations were determined
spectrophotometrically at 240 nm (ε=43.6 M−1.cm−1[18,19].
Dopamine oxidation was measured spectrophotometrically at
476 nm. A 1-ml cuvette contained 880 μl 50 mM Tris–HCl buffer, pH
7.2, containing 1 mM diethyltriaminepentaacetic acid (DTPA); 50 μl
cytochrome cpx (100 μg/ml); and 20 μl 40 mMdopamine. The reaction
was started by the addition of 50 μl 100 mM H2O2.
2.2.3. Oxidation of sulfhydryl groups by SOD1 peroxidase
Oxidation of sulfhydryl group-containing substances was deter-
mined by following the disappearance of sulfhydryl groups using the
Fig. 2. Absorption spectra of 0.05 mM oxidized and reduced ABTS in phosphate-citrate
buffer, 50 mM each, at pH 5.4. Reduced ABTS is virtually colorless, whereas oxidized
ABTS is dark green. From Everse et al. [24], with permission.
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Wright and Viola [20]. The sulfhydryl group-containing compound
was dissolved in 10 ml 50 mM Tris–HCl buffer, pH 7.2, containing
1 mM DTPA, to a ﬁnal concentration of 33 mM. Added were 50 μl
cytochrome cpx (1 mg/ml). 0.9 ml was then transferred to a 1-ml
cuvette and 50 μl 1 M tris buffer, pH 8.0, and 50 μl distilled water were
added to the cuvette, followed by rapid mixing and recording the
absorbance of the solution at 412 nm (value a). Another 0.9 ml aliquot
was then transferred to another 1-ml cuvette and the experiment was
repeated, except that 50 μl 30 mMDTNB solution in tris buffer, pH 8.0,
was added instead of the water (value b). The net absorbance (value b
−a) was considered the absorbance of 100% SH groups. To start the
reaction, 50 μl of 1.0 M H2O2 were then added to the 10 ml reaction
mixture and at the indicated times 0.9 ml aliquots were removed,
treated as abovewith DTNB and the absorbance of the treated solution
was determined (value c). The decrease in SH content was then
determined by subtracting value c from value b. Percentage SH groups
oxidized was then determined as (b−c)/(b−a). All reactions and
measurements were carried out at 37 °C.Fig. 3. Progression of cytochrome c proteolysis with pepsin. Cytochrome c (0.1 mM)
was treated with pepsin at room temperature and pH 2.6. At the indicated time
intervals aliquots of the reaction mixture were removed and the peroxidase activity
was determined as described in Section 2.2.2.2.2.4. Assay for cytolytic activity
The assay to measure the rate of cytolysis, catalyzed by a
peroxidase is described in detail elsewhere [21,22]. Brieﬂy, cytolysis
can be measured spectrophotometrically by measuring the decrease
in turbidity that occurs when cells lyse. This decrease is most
pronounced with erythrocytes, which do not contain nuclei, mito-
chondria, and other insoluble bodies that cause a remaining amount
of turbidity and therefore yield much more “noisy” curves [23]. The
decrease in turbidity can be conveniently measured at a wavelength
where absorbance of all components in the cuvette is minimal. We
have routinely used 600 nm for this purpose. It is a prerequisite that
the cells be dispersed in an isotonic buffer in order to prevent the
occurrence of non-catalyzed cell lysis. All cytolytic assays were
performed at 37 °C.
A typical assay for cytolytic activity is done in a 3-ml cuvette,
which contains about 2×106 rabbit erythrocytes, 200 μMH2O2, 25 μM
potassium iodide and 100 μg cytochrome cpx in 9.5 mMNa-phosphate
buffer, pH 7.5, containing 140 mM NaCl. Reactions were started with
the addition of H2O2. Reference cuvettes contained all ingredients,
except the erythrocytes. Erythrocytes were separated from 1 to 2 mlfreshly drawn rabbit blood, obtained via the ear vein. This procedure
was approved by the Institutional Animal Care and Use committee.
3. Results
3.1. Assay for peroxidase activity
ABTS is one of the more sensitive substrates to measure
peroxidase activity. The generation of oxidized ABTS by a peroxi-
dase is usually followed spectrophotometrically at 410 nm. Howev-
er, this is close to the Soret absorption band of cytochrome c, which
makes ABTS less suitable to use as a substrate for measuring the
peroxidase activity of cytochrome c. But oxidized ABTS has also a
large absorption maximum above 700 nm, where the absorbance of
cytochrome c is negligible (Fig. 2). We made use of this property in
the past when we measured the peroxidase activity of methemo-
globin [24]. Accordingly, in the present study we used 740 nm as
the wavelength for measuring the catalytic activity of cytochrome
cpx. We determined the extinction coefﬁcient of oxidized ABTS at
740 nm to be 23,480 M−1 cm−1.
3.2. Formation of cytochrome cpx by proteolysis
Pepsin has been the protease of choice to catalyze the conversion
of cytochrome c to its peroxidase form in vitro on a preparative scale
[25,26]. Fig. 3 shows the generation of peroxidase activity as a
function of time when cytochrome c is hydrolyzed with pepsin using
the procedure described in Section 2.2. Maximum speciﬁc activity was
obtained after a 90-min incubation. Pepsin-catalyzed hydrolysis will
continue after 90 min but may cause some loss of peroxidase activity.
Incubation of a cytochrome c solution for 20 hours in the absence of
pepsin results in a spontaneous generation of a small amount of
peroxidative activity, as indicated in Fig. 3.
It should be mentioned that acidiﬁcation of a cytochrome c
solution in the absence of any proteolytic enzyme leads to about a 5-
Fig. 5.Oxidation of coenzyme A by 1 mMH2O2 and cytochrome cpx. Coenzyme A (30 μM
in 50 mM Tris–HCl buffer, pH 7.2, containing 1 mM DTPA) was incubated with or
without the indicated amount of cytochrome cpx at 37 °C for the indicated times.
Remaining concentrations of coenzyme A were determined with the DTNB method as
described in Section 2.2.3.
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reversed when the solution is subsequently neutralized again, even
when the pH was adjusted to as low as 1.1. This may be caused by a
partial and reversible unfolding of the cytochrome at low pH.
Mass spectroscopy results show that pepsin causes a hydrolysis
of the cytochrome at Leu64 and at Glu66 (see Fig. 1), yielding two
peptides of 7675 and 7937 Da, each having peroxidase activity, as
well as two inert (and colorless) peptides of 4266 and 4583 Da
(Fig. 4). Preparing cytochrome cpx, as described in Section 2.2,
yields a preparation that contains a mixture of the two heme-
containing peptides. Such a preparation was used in the experi-
ments described below.
A similar hydrolysis experiment in which trypsin was used as the
hydrolytic enzyme at pH 7.2 did not result in the generation of any
signiﬁcant amount of peroxidase activity.
3.3. Oxidation of various metabolites and antioxidants by cytochrome cpx
As is characteristic for most heme-containing peroxidases,
cytochrome cpx in the presence of H2O2 will oxidize a large variety
of compounds. Besides ABTS, the compounds that can also serve as
substrates include reduced glutathione, L-DOPA, dopamine, N-
acetylcysteine, minocycline, curcumin, 3-aminotyrosine, desferal,
apomorphine, dimercaptopropanol, and clioquinol, among many
others.
Coenzyme A is slowly oxidized to the disulﬁde form in the
presence of low millimolar concentrations of H2O2. This oxidation is
signiﬁcantly accelerated in the presence of cytochrome cpx, as
shown in Fig. 5. Thus, the presence of 2 μg cytochrome cpx causes a
5-fold acceleration in the rate of coenzyme A oxidation by 1 mM
H2O2.
3.4. Inhibition of dopamine oxidation by various antioxidants
Since it is well established at this point that the excess H2O2,
produced by dysfunctional mitochondria in parkinsonian brain cells
as well as by activated microglial cells surrounding the affected
neurons, is a participant in the neuronal degeneration, removal of
this excess H2O2 may cause an attenuation of the degenerative
process. This could be achieved by supplying the brain with
antioxidant compounds that are more readily oxidized than cellularFig. 4. Mass spectroscopy results showing the products obtacomponents such as dopamine. Accordingly, we tested a variety of
antioxidants for their ability to inhibit the oxidation of 800 μM
dopamine in vitro. These compounds included curcumin, caffeic
acid, 3-aminotyrosine, minocycline, N-Ac-cysteine, cysteine, GSH,
dimercaptopropanol, and Na-2-mercaptoethane-sulfonate (MESNA).
Of these, cysteine, N-Ac-cysteine and GSH were oxidized much
faster than dopamine, as shown by a lag time in the oxidation of
dopamine (Fig. 6). A 50% inhibition of the rate of 800 μM dopamine
oxidation was observed with 150 μM 3-aminotyrosine, 80 μM
MESNA, and 30 μM dimercaptoethanol. MESNA and dimercap-
toethanol are sulfhydryl compounds commonly used as antidotes
against lead and mercury poisoning. Caffeic acid at 0.5 mM as wellined from the proteolysis of cytochrome c with pepsin.
Fig. 6. Inhibition of the cytochrome cpx-catalyzed oxidation of dopamine by cysteine.
Conditions: 800 μM dopamine, 5 μg cytochrome cpx, 5 mM H2O2, and the indicated
concentrations of cysteine in 1 ml 50 mM Tris–HCl buffer, pH 7.2, containing 1 mM
DTPA. Assays were done at 37 °C.
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shown to have considerable beneﬁcial effects toward both Parkin-
son's and Alzheimer's diseases [27–30]. Inhibition of dopamine
oxidation by curcumin is shown in Fig. 7. Note that each of the
tested compounds is also a substrate for cytochrome cpx; therefore
the observed inhibition is caused by a competition betweenFig. 7. Inhibition of the cytochrome cpx-catalyzed oxidation of dopamine by curcumin.
Conditions were the same as in Fig. 6, except the indicated concentrations of curcumin
were used instead of cysteine.dopamine and the compound tested for the active site of the
peroxidase.3.5. Inactivation of cytochrome cpx by H2O2
In the absence of any substrate, cytochrome cpx is rapidly
inactivated by relatively low concentrations of H2O2. This appears to
be a self-oxidation of the enzyme. This self-oxidation is also
apparent during assays with some slow-oxidizing substrates,
which show a signiﬁcant decrease in activity with time. Thus, the
oxidation of coenzyme A shows that after about 10 min the rate
becomes similar to that of the uncatalyzed rate (Fig. 5), suggesting
that under these assay conditions it takes about 10 min for the
cytochrome cpx to become inactivated. Addition of a second aliquot
of the peroxidase to an assay mixture after the rate has decreased to
that of the uncatalyzed reaction restores the initial rate, indicating
that the decrease in rate is not caused by a decrease in substrate
concentration (data not shown).3.6. Cytolytic properties of cytochrome cpx
Cytochrome cpx in the presence of certain halides will promote the
cytolysis of various cells in a reaction similar to that of myeloperox-
idase [31,32], lactoperoxidase [23], horseradish peroxidase [22], and
hemin [33]. A typical example is shown in Fig. 8, illustrating the rate of
cytolysis of rabbit erythrocytes at various concentrations of H2O2. No
lysis occurs in the absence of KI or in the absence of H2O2. The rate of
lysis is pH dependent and shows a rather sharp maximum at pH 7.5
(data not shown).
This lytic activity of cytochrome cpx is inhibited by a variety of
compounds, including dopamine, reduced glutathione, apomorphine,
desferal, 3-aminotyrosine, minocycline and L-DOPA. The most potent
of these compounds was 3-aminotyrosine, which completely inhib-
ited cell lysis at 5 μM, followed by minocycline, which inhibited
completely at 20 μM. All other compounds required concentrations ofFig. 8. Hydrogen peroxide dependence of the cytolytic activity of cytochrome cpx.
Cytolytic activity of cytochrome cpx toward rabbit erythrocytes was determined
spectrophotometrically at 37 °C as described in Section 2.2.4.
Fig. 9. Inhibition of the cytolytic activity of cytochrome cpx by L-DOPA. Conditions:
2×106 rabbit erythrocytes, 0.2 mM H2O2, 26 μM KI, 100 μg cytochrome cpx, and the
indicated amounts of a 0.5 mM L-DOPA solution. Other conditions as described in
Section 2.2.4.
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4. Discussion
4.1. Conversion of cytochrome c to cytochrome cpx
The conversion of cytochrome c to a peroxidase, using much less
drastic conditions than the extensive proteolysis used by Harbury and
Loach [14], has been observed for several years. Thus, treatment of
cytochrome c with concentrations of H2O2 between 0.1 and 1 mM
results in the generation of peroxidase activity [34,35]. Also, nitration
of tyr67 of the cytochrome leads to a large increase in its peroxidase
activity [36]. Furthermore, Burkitt and his colleagues showed that in
the presence of 250 μMH2O2 cytochrome c becomes a compoundwith
peroxidase activity, and these authors proposed that this form of
cytochrome c may play an important role in redox signaling in
apoptosis [4,13,37]. Kagan and co-workers [38] showed that cyto-
chrome c binds avidly to phosphatidylserine, yielding a complex with
potent peroxidase activity that readily catalyzes the peroxidation of
lipids. Following release from the mitochondrial inner membrane,
cytochrome c can also bind to the cardiolipin that is present in the
inner membrane. Kagan and colleagues performed detailed studies on
the structural and biochemical properties of the cytochrome c/
cardiolipin complex. This complex has potent peroxidase activity
and promotes the oxidation of the cardiolipin [39]. They subsequently
showed that as a result of the binding to cardiolipin, cytochrome c
undergoes a conformational change that results in a dissociation of
the Fe-methionine ligand [40,41], which explains the generation of
peroxidase activity by the cardiolipin-bound cytochrome. Finally,
Mizuta et al. [42] showed that in mouse ﬁbroblasts stimulated with a
combination of the calcium ionophore A23187 and arachidonic acid,
cytosolic serine proteases not only caused the release of cytochrome c
from the mitochondrial membrane but that these proteins are also
somehow involved in causing cell death. The latter observation could
indicate that the proteases converted the cytochrome to cytochrome
cpx, which in turn caused cell death bymeans of its oxidative actions. Ifsuch a reaction should also occur in affected neurons, it is possible that
cytochrome c, following proteolysis and now acting as a peroxidase,
may at least be partly responsible for the oxidation of important
metabolites (reduced glutathione, coenzyme A, dopamine, etc.) as
well as of life-sustaining proteins and lipids.
4.2. Peroxidase activity in vivo
Peroxidases and pseudo-peroxidases are present in many cell
types. Usually, these enzymes are inactive, because their essential
substrate, H2O2, is lacking. However, when an H2O2 generating system
is activated, peroxidases will start exerting their oxidative actions.
Such is the case, for example, in polymorphonuclear leukocytes,
which are rich in myeloperoxidase. Activation of these cells includes
an activation of their NADPH oxidase, which initiates the generation
of H2O2. This in turn allows myeloperoxidase to exert its destructive
action, leading to the cytolysis of any phagocytosed organism [43].
In vivo concentrations of H2O2 in brain tissues are not yet well
established. This is largely due to the rapid inﬂux and efﬂux of H2O2
through cellular and mitochondrial membranes. Catalase and gluta-
thione peroxidase prevent a build-up of any H2O2 that may be formed
by cellular oxidases or by the mitochondrial electron transport chain
under normal conditions. Steady state concentrations have been
estimated to be as low as a few μM [44,45]; however, H2O2
concentrations up to 100 μM are generally considered to be
physiological concentrations [54–57]. In parkinsonian brain tissues,
however, this concentration could be considerably higher, consider-
ing the high rate at which activated microglia produce H2O2[52,53]. In
addition, the malfunctioning electron transport chain also produces
an unknown amount of H2O2. When the rate of H2O2 production
exceeds the capacity of catalase and glutathione peroxidase to
neutralize the H2O2, any peroxidases that are present in the affected
neurons, including any cytosolic cytochrome cpx, may become active
under those conditions and cause oxidative damage to cellular
components.
4.3. Consequences of coenzyme A oxidation
The fact that a depletion of reduced glutathione occurs in
parkinsonian neurons is well established [46–48]. We found that
oxidation of reduced glutathione is catalyzed by cytochrome cpx. In
vivo, oxidized glutathione can be reduced again by glutathione
reductase with the aid of NADPH, thus providing a mechanism for
the regeneration of reduced glutathione. Our results show that
coenzyme A is also oxidized by H2O2, and the rate of oxidation is
accelerated by cytochrome cpx. This indicates that this important
cofactor is probably also subject to oxidation in parkinsonian neurons,
albeit at a slower rate than GSH oxidation. However, mammals do not
have a coenzyme A reductase. Therefore, maintenance of functional
cellular coenzyme A levels will depend on either a disulﬁde transfer,
which requires high levels of reduced glutathione, or biosynthesis of
new coenzyme A, which requires the availability of a continuous
supply of pantothenic acid (vitamin B5). Whether the levels of
coenzyme A in affected brain cells are low is currently not known, but
indirect evidence suggests that they are. Since the brain is highly
dependent on either the aerobic oxidation of glucose or ketone bodies
as its energy sources, both of which require coenzyme A as an
essential cofactor, it follows that a signiﬁcant depletion of functional
coenzyme A could be a contributing factor in the demise of affected
neurons in parkinsonism.
A lack of sufﬁcient amounts of coenzyme A would cause the
brain to be more dependent on glycolysis for its ATP production,
causing increased levels of brain lactate. Increased levels of lactate
were indeed detected in both Parkinson patients and in animal
models [49–51].
1144 J. Everse et al. / Biochimica et Biophysica Acta 1812 (2011) 1138–1145Furthermore, Parkinson's patients in general have low cholesterol
levels and 3-hydroxy-3-methyl-glutaryl-CoA reductase, the rate-
limiting enzyme in cholesterol biosynthesis, was found to be reduced
in Parkinson's patients [52,53]. Given the role of coenzyme A in sterol
biosynthesis, a deﬁciency in coenzyme A could explain these
observations.
Biochemical analyses of brains from Parkinson's patients also show
decreased levels of phosphatidylethanolamine, phosphatidylcholine
and polyunsaturated fatty acids [54–56]. Again, since coenzyme A is
required for the biosynthesis of these compounds, such results may be
expected in cases where a deﬁciency in coenzyme A exists.
Given these considerations, it is of considerable importance that
studies be performed analyzing affected tissues for their coenzyme A
content as well as for the possible presence of cytochrome cpx.
4.4. Inhibition of dopamine oxidation by various compounds
Several anti-oxidant compounds were shown to have an attenu-
ating effect on the neurodegenerative progression in Parkinson's
patients and/or animal models (e.g. [57,58]). If neuronal damage
during neurodegeneration is in part caused by the excessive
production of H2O2, then removal of the H2O2 before it can oxidize
important cellular metabolites or enzymes should result in an
attenuation of the progression of neurodegeneration. This can
theoretically be accomplished by the administration of oxidizable
compounds that have a lower Km for the peroxidase than the cellular
metabolites and would therefore be oxidized preferentially, thereby
depleting excess H2O2. To be effective in vivo, such compounds have to
be able to pass the cell membrane as well as the blood–brain barrier,
and the compound itself as well as its oxidation product(s) should be
non-toxic. For this reason we investigated if and to what extent
various relevant compounds inhibit the oxidation of dopamine by
cytochrome cpx. Currently, L-DOPA is used as a drug in parkinsonism
in an attempt to replenish the dopamine in neuronal cells. A different
strategy may be to use drugs that are oxidized preferentially to
dopamine, and may therefore result in a retention of dopamine levels
in affected cells.
A considerable amount of research has shown a role of α-
synuclein in vesicle trafﬁcking and its toxic effects in parkinsonism
(for a recent review, see [59]). Four tetrahydroquinolinoles were
recently identiﬁed that protect against these toxic effects [60]. These
compounds also protect against rotenone toxicity in rat midbrain
neurons. The authors conclude that “these compounds must be
acting on some deeply rooted biological process, linking α-
synuclein toxicity, vesicle trafﬁcking defects, and mitochondrial
dysfunction” [59]. We propose that this process may be the
oxidative actions of cytochrome cpx and H2O2.
4.5. Cytolysis in Parkinson's disease
The cytolytic activity of cytochrome cpx indicates that this
peroxidase is also capable of causing severe damage to membrane
structures. The possibility that the cytolytic action of certain
peroxidases may also take part in the destructive mechanism of
neurodegeneration has so far not been considered. It is known that
various heme-containing peroxidases, as well as hemin itself, catalyze
cell lysis in the presence of H2O2 and a halide ion [22,23,33,43]. If it
can be shown that cytochrome cpx is present in parkinsonian neurons,
then the possibility of cytolytic action participating in neurodegen-
eration should receive serious consideration.
4.6. Peroxidase involvement in other neurodegenerative diseases
Citing experimental results we concluded earlier that the
biochemical processes leading to neurodegeneration are very similar,
if not the same in several neurological diseases, including Parkinson'sand Alzheimer's diseases as well as ALS, and that the oxidative
reactions are most likely catalyzed by a peroxidase [3]. Current
information suggests that the identity of this peroxidase may not be
the same among the various neurodegenerative diseases. Thus, the Aβ
peptide is known to be intimately associated with Alzheimer's
disease. This peptide was shown to bind heme with high afﬁnity,
and the product possesses peroxidase activity [61–63]. Similarly, it is
well established that Cu,Zn-superoxide dismutase is intimately
involved in ALS. This enzyme, when exposed to H2O2, transforms
into a peroxidase [64–66]. This peroxidase was recently shown to be
present in the nuclei and cytosol of ALS transfected SH-SY5Y cells but
not in normal SH-SY5Y cells [67]. These ﬁndings lend further support
to our hypothesis that peroxidases may be intimately involved in
neurodegeneration.
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